Journal of allergy and clinical immunology, 2013, Vol.132 (2), p.482-485.e10
Byline: E. Marije Bakker (a), Els C. van der Wiel-Kooij (a), Bernhard Mullinger (b), Philipp Kroneberg (b), Wim C.J. Hop (c), Harm A.W.M. Tiddens (a) Author Affiliation: (a) Department of Pediatric Pulmonology, Erasmus MC-Sophia Children's Hospital, Rotterdam, The Netherlands (b) Activaero GmbH, Gemunden, Germany (c) Department of Biostatistics, Erasmus MC, Rotterdam, The Netherlands Article Note: (footnote) Supported by Roche Netherlands B.V., Stichting Vrienden van het Sophia (Friends of Sophia Children's Hospital Foundation), Stichting Astma Bestrijding (Dutch Fund for Asthma), and Activaero GmbH. Roche BV Netherlands supplied dornase alfa for use in this study free of charge., Disclosure of potential conflict of interest: E. M. Bakker has been supported by one or more grants from Stichting Astma Bestrijding. B. Mullinger is employed by, has one or more patents (planned, pending, or issued) with, and owns stock/stock options in Activaero. P. Kroneberg is employed by and has one or more patents (planned, pending, or issued) with Activaero. A. W. M. Tiddens has been supported by one or more grants from Roche Pharmaceuticals; has consultancy arrangements with Gilead, Novartis, Pharmaxis, Insmed, and Siemens; is employed by the University of Washington (Visiting Professorship [grant by CFF]) and by the University of Cincinnati (Visiting Professorship [grant by CFF]); has received one or more payments for lecturing from or is on the speakers' bureau for Roche, Gilead, and Novartis; and has a combined patent on specific targeting with DNase. The rest of the authors declare that they have no relevant conflicts of interest.
Abridged Index Medicus ; Adolescent ; Airway Obstruction - drug therapy ; Airway Obstruction - physiopathology ; Allergy and Immunology ; Asthma - complications ; Asthma - drug therapy ; Asthma - physiopathology ; Asthma in children ; Biological and medical sciences ; Child ; Deoxyribonuclease I - metabolism ; Deoxyribonuclease I - therapeutic use ; Dornase alfa ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Male ; Maximal Midexpiratory Flow Rate ; Medical sciences ; Nebulizers and Vaporizers ; Recombinant Proteins - metabolism ; Recombinant Proteins - therapeutic use ; Sarcoidosis. Granulomatous diseases of unproved etiology. Connective tissue diseases. Elastic tissue diseases. Vasculitis ; Treatment Outcome
Backfile Package - All of Back Files EBS [ALLOFBCKF]
http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=27609676$$DView record in Pascal Francis
Permalink to record
https://www.ncbi.nlm.nih.gov/pubmed/23541323$$D View this record in MEDLINE/PubMed